NOVO NORDISK ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly making false and misleading statements regarding the company's phase 3 CagriSema study on obesity, which may have misled investors during the class period from November 2, 2022, to December 19, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey on behalf of all individuals and entities who purchased Novo Nordisk securities during the specified class period [1]. - Investors have until March 25, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Novo Nordisk - The complaint alleges that the defendants created a false impression of possessing reliable information regarding the successful outcome of the CagriSema study while avoiding discussions on dosage tolerability [3]. - It is claimed that Novo Nordisk's optimistic assertions that CagriSema would achieve at least 25% weight loss in the REDEFINE-1 study did not align with actual results [3]. - The use of a "flexible protocol" in the study is said to have limited its ability to provide effective weight loss data, suggesting potential issues with dosage tolerability or a rushed patient selection process [3].